175 related articles for article (PubMed ID: 19363781)
1. The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
Ketteler M
Int J Artif Organs; 2009 Feb; 32(2):95-100. PubMed ID: 19363781
[TBL] [Abstract][Full Text] [Related]
2. Dietary and pharmacological control of calcium and phosphate metabolism in predialysis stages of chronic kidney disease.
Ketteler M; Biggar PH
Blood Purif; 2009; 27(4):345-9. PubMed ID: 19295197
[TBL] [Abstract][Full Text] [Related]
3. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Hanba Y; Masumoto A; Moribata M; Shigemathu T
Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
[TBL] [Abstract][Full Text] [Related]
4. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Cozzolino M; Brancaccio D
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
[TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
8. [Use of phosphate binder in predialysis patients].
Taniguchi M
Clin Calcium; 2009 Feb; 19(2):229-35. PubMed ID: 19182364
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
11. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
[No Abstract] [Full Text] [Related]
12. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
13. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
Mudge DW; Johnson DW; Hawley CM; Campbell SB; Isbel NM; van Eps CL; Petrie JJ
BMC Nephrol; 2011 May; 12():20. PubMed ID: 21569446
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
15. Oral phosphate binders.
Hutchison AJ
Kidney Int; 2009 May; 75(9):906-14. PubMed ID: 19279554
[TBL] [Abstract][Full Text] [Related]
16. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
17. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
18. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
Ohno M; Ohashi H; Oda H; Yokoyama H; Okada M; Nagaya M; Izumi K; Ito H; Katoh S
Perit Dial Int; 2013; 33(3):297-303. PubMed ID: 23209037
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
20. Phosphate binders in CKD: chalking out the differences.
Rees L; Shroff RC
Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
